abcam

ab150427

Anti-LGALS14 antibody [EPR9665]

Recombinant | RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Clone number	EPR9665
Purification technique	Affinity purification Protein A
Concentration	1.253 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

IP

Not recommended

Species	Mouse, Human
Dilution info	-
Notes	-

WB

Tested

Species	Mouse
Dilution info	1/1000 - 1/10000
Notes	-

Species	Human
Dilution info	1/1000 - 1/10000
Notes	-

IHC-P

Not recommended

Species	Mouse, Human
Dilution info	-
Notes	-

ICC/IF

Tested

Species	Human
Dilution info	1/100 - 1/250
Notes	-

Expected

Species	Mouse
Dilution info	Use at an assay dependent concentration.
Notes	-

Flow Cyt (Intra)

Tested

Species	Human

Dilution info	1/20
Notes	-

Expected

Species	Mouse
Dilution info	Use at an assay dependent concentration.
Notes	-

Target data

See full target information LGALS14

Function	Binds beta-galactoside and lactose. Strong inducer of T-cell apoptosis.

Storage

Shipped at conditions	Conditional Ambient
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C

Notes

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Species reactivity
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species.
Please contact us for more information.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	LGALS14 also known as Galectin-14 is a member of the galectin family a group of beta-galactoside-binding proteins. It has a mass of around 14 kDa. This protein is expressed highly in eosinophils and placenta tissues. As a carbohydrate-binding protein LGALS14 participates in cellular interactions and its expression level may vary depending on cell activation states or pathological conditions.
Biological function summary	Galectin-14 functions in the immune response and regulation of inflammation. It can influence cell apoptosis and modulate signaling pathways through binding to specific carbohydrate moieties on cell surfaces. LGALS14 itself is not typically part of bigger protein complexes although it might interact with other galectins or proteins in certain cellular contexts to carry out its functions more effectively.
Pathways	This galectin family member holds a role in the immune system especially within pathways that manage inflammatory responses. It interacts with proteins such as Galectin-3 and Galectin-9 which also contribute to inflammatory regulation and immune function. These interactions help modulate immune signaling and processes like cell adhesion which are key components of the immune response pathway.
Associated diseases and disorders	LGALS14 associates with conditions such as asthma and inflammatory bowel disease (IBD). In asthma Galectin-14 levels often correlate with eosinophil activity which is an indicator of inflammation severity. Furthermore research links LGALS14 with inflammation in IBD possibly through its role in modulating like Galectin-3 which also participate in inflammation pathways. Understanding its interactions and expression can provide insights into these diseases' mechanisms and potential therapeutic targets.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


6 product images



Immunocytochemistry/ Immunofluorescence - Anti-LGALS14 antibody [EPR9665] (ab150427)

LGALS14 Immunocytochemistry/ Immunofluorescence staining using rabbit Anti-LGALS14 antibody


Immunocytochemistry/ Immunofluorescence analysis of JAR (Human placenta choriocarcinoma epithelial cell) cells labeling LGALS14 with purified ab150427 at 1/100 dilution (10 µg/ml). Cells were fixed in 4% Paraformaldehyde. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1/200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.



Immunocytochemistry/ Immunofluorescence - Anti-LGALS14 antibody [EPR9665] (ab150427)

LGALS14 Immunocytochemistry/ Immunofluorescence staining using rabbit Anti-LGALS14 antibody


Immunofluorescent analysis of JAR cells labelling LGALS14 with unpurified ab150427 at 1/100 dilution.



Flow Cytometry (Intracellular) - Anti-LGALS14 antibody [EPR9665] (ab150427)

LGALS14 Flow Cytometry (Intracellular) staining using rabbit Anti-LGALS14 antibody

Intracellular Flow Cytometry analysis of JAR (Human placenta choriocarcinoma epithelial cell) cells labeling LGALS14 with purified ab150427 at 1/20 dilution (10 µg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).



Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427)

All lanes:
Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427) at 1/1000 dilution


All lanes:
Human placenta lysates at 15 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Predicted band size: 16 kDa

Observed band size: 16 kDa



Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427)


All lanes:
Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427) at 1/1000 dilution

All lanes:
Mouse placenta lysate at 10 µg

Secondary

All lanes:
Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 16 kDa



Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427)

All lanes:
Western blot - Anti-LGALS14 antibody [EPR9665] (ab150427) at 1/1000 dilution

All lanes:
Human placenta lysate at 10 µg

Secondary

All lanes:
Goat anti-rabbit HRP at 1/2000 dilution

Predicted band size: 16 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.